What Dalvance treats.
- Acute bacterial skin and skin structure infections (ABSSSI)
- Cellulitis
- Wound infections
- Major cutaneous abscesses
- MRSA infections (methicillin-resistant Staphylococcus aureus)
The mechanism.
Dalvance (dalbavancin) is a lipoglycopeptide antibiotic that disrupts bacterial cell wall synthesis, killing gram-positive organisms including MRSA. Its long half-life means a single dose — or a two-dose regimen — provides therapeutic blood levels for one to two weeks. This makes it a powerful outpatient alternative to multi-day IV antibiotic hospitalizations for skin and soft tissue infections.
Your Dalvance infusion experience.
Dalvance is administered as a 30-minute IV infusion. Most patients receive a single 1500 mg dose, or a two-dose regimen (1000 mg followed by 500 mg one week later). Compared to traditional IV antibiotic protocols requiring daily infusions or hospitalization, Dalvance lets you complete treatment in one or two outpatient visits. Your prescribing physician will determine which protocol fits your infection.
Insurance & out-of-pocket cost.
Dalvance is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.